| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
30,358 |
23,879 |
$2.12M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
19,161 |
15,334 |
$1.35M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
30,172 |
23,777 |
$1.35M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
10,570 |
7,962 |
$1.09M |
| 99051 |
|
49,815 |
40,384 |
$255K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
3,369 |
2,732 |
$86K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,947 |
3,914 |
$37K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,008 |
882 |
$18K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
3,624 |
2,304 |
$6K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
746 |
521 |
$4K |
| 87428 |
|
65 |
17 |
$250.65 |
| 71046 |
Radiologic examination, chest; 2 views |
12 |
12 |
$233.28 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
134 |
120 |
$8.40 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
146 |
93 |
$7.07 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
183 |
135 |
$4.92 |
| 99000 |
|
181 |
172 |
$0.00 |
| 99072 |
|
18,765 |
14,432 |
$0.00 |
| 81003 |
|
13 |
12 |
$0.00 |